Compare AbCellera Biologics Inc (ABCL) vs KraneShares Hang Seng TECH Index ETF (KTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs KraneShares Hang Seng TECH Index ETF — how do they compare? AbCellera Biologics Inc trades at $9.29 (market cap $2.85B), while KraneShares Hang Seng TECH Index ETF trades at $13.5. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, KraneShares Hang Seng TECH Index ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | KTEC | |
|---|---|---|
Market Cap | $2.85B | — |
Sector | Health | Sector/Thematic |
52-Week High | $9.34 | $19.51 |
52-Week Low | $2.78 | $12.00 |
Enterprise Value | $2.45B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
KTEC trades at $13.78, up 1.47% today, with a bullish technical signal driven by moving averages. Support and resistance cluster at $14, indicating a critical price zone. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights China's AI competition as a potential catalyst for tech ETFs like KTEC.
The stock's outlook hinges on AI sector momentum, but risks include reliance on thematic trends and lack of disclosed financials. Upside depends on broader tech ETF inflows, while volatility from geopolitical or market shifts poses a near-term challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →
